OncoMatch/Clinical Trials/NCT06377371
Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Is NCT06377371 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies non-drug interventions for meningioma.
The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device.
Check if I qualifyExtracted eligibility criteria
Demographics
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- New York-Presbyterian/Weill Cornell Medical Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06377371 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify